#USA #Toronto #Clinical Trials #ADPKD #Polycystic Kidney Disease

Overview of the Webinar on Polycystic Kidney Disease

A free-to-attend webinar is set to provide valuable insights into polycystic kidney disease (PKD), particularly focusing on autosomal dominant PKD (ADPKD). The event will take place on Thursday, December 4, 2025, at 11 AM EST. Participants will hear from experienced professionals in the field who will address crucial topics, including the challenges of patient recruitment for ADPKD clinical trials and the current clinical presentations of affected patients.

Understanding Polycystic Kidney Disease (PKD)

Polycystic kidney disease affects millions of individuals globally, with about 600,000 cases in the United States alone, making it the fourth most common cause of kidney failure. Approximately 90% of these cases involve the autosomal dominant form (ADPKD), resulting from a mutation in one of two genes, PKD1 or PKD2. Despite advancements in genetic testing, no cure currently exists for this inherited disorder.

ADPKD affects roughly 12 million people worldwide, highlighting the importance of ongoing research and new treatment options. The Kidney Disease Improving Global Outcomes (KDIGO) has recently recommended improved biomarkers to better understand ADPKD progression, urging researchers to develop more effective predictive models based on serum proteomics.

Key Focus of the Webinar

The featured experts for the upcoming webinar include Dr. Sayna Norouzi, an Associate Professor of Medicine at Loma Linda University Medical Center and the founder of the clinic specializing in PKD and glomerular diseases. Alongside Dr. Norouzi, Dr. Hannah Troutman, a nephrologist and Associate Medical Director, will also share insights into the latest research developments. The session will be moderated by Sarah Dixon Stump, the Senior Director of Project Oversight at PPD Clinical Research.

Attendees can expect discussions around the evolving landscape of ADPKD treatment and the complexities involved in conducting clinical trials. Special attention will be dedicated to recent advancements, including the approval of the drug tolvaptan in 2015 and 2018, and the growing pipeline of new therapeutic options currently under investigation.

Challenges and Opportunities

The webinar aims to shed light on the novel challenges that researchers and healthcare professionals face when addressing ADPKD treatment. As research moves forward, it is essential to consider the implications of primary cilia dysfunction, which is a critical aspect of various ciliopathies, including ADPKD. This highlights the opportunity for innovative therapy directions focusing on cellular metabolism and potential target areas such as asparagine synthetase (ASNS).

As the pharmaceutical landscape continues to change, the demand for safe and effective treatments for ADPKD remains urgent. The featured speakers will provide essential insights into ongoing research initiatives and the potential impact on future patient outcomes.

How to Participate

For those interested in joining this informative session, registering for the webinar is encouraged to gain comprehensive knowledge on how clinical trials in polycystic kidney disease are shaping the prospective landscape of ADPKD treatment. The registration link can be found on the Xtalks website.

Stay informed on critical updates and developments in PKD treatment from industry experts and contribute to the discourse aimed at enhancing the quality of life for those affected by ADPKD. Don’t miss out on this opportunity to learn from leading figures in the field!

Conclusion

The forthcoming webinar on polycystic kidney disease highlights significant areas of research and development that could lead to improved treatment options for ADPKD patients. By participating, attendees will be equipped with the latest information regarding clinical trial dynamics and the future of therapeutic interventions.